ConcR is a predictive software platform built to combat cancer. The company combines cutting-edge machine learning techniques taken from astrophysics with deep scientific understanding of tumour progression to accurately predict cancers’ evolution in response to treatment. This will enable clinicians to adapt treatments proactively, rather than reactively, to prevent treatment resistance and improve treatment efficacy through precision medicine.

Avonmore co-invested into ConcR’s initial pre-seed round in 2021 alongside several other members of the Cambridge Angels group. In 2023 it closed a $1.5M seed round led by Cambridge Enterprise.